NCT00742859 - Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | Biotech Hunter

Enrollment

508

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

November 30, 2009

Conditions

Atrial Fibrillation

Interventions

DRUG

betrixaban

orally, once daily for at least 3 months

DRUG

Warfarin

Warfarin will be prescribed by the investigator according to the standard of care.

Trial Locations (21)

12601

Portola Investigational Site, Poughkeepsie

19096

Portola Investigational Site, Wynnewood

21044

Portola Investigational Site, Columbia

21204

Portola Investigational Site, Towson

21804

Portola Investigational Site, Salisbury

23507

Portola Investigational Site, Norfolk

32174

Portola Investigational Site, Ormond Beach

32501

Portola Investigational Site, Pensacola

32901

Portola Investigational Site, Melbourne

33173

Portola Investigational Site, Miami

33952

Portola Investigational Site, Port Charlotte

38801

Portola Investigational Site, Tupelo

57701

Portola Investigational Site, Rapid City

60504

Portola Investigational Site, Aurora

63110

Portola Investigational Site, St Louis

80909

Portola Investigational Site, Colorado Springs

92801

Portola Investigational Site, Anaheim

97123

Portola Investigational Site, Hillsboro

04210

Portola Investigational Site, Auburn

Unknown

Portola Investigational Site, Longueuil

Portola Investigational Site, Montreal